MEDICINOVA INC (MNOV) Stock News

USA - NASDAQ:MNOV - US58468P2065 - Common Stock

1.25 USD

+0.01 (+0.81%)

Last: 10/14/2025, 1:22:07 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MNOV Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: MediciNova, Inc.

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

8 days ago - By: MediciNova, Inc.

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

22 days ago - By: MediciNova, Inc.

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

a month ago - By: MediciNova, Inc.

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

a month ago - By: MediciNova, Inc.

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

a month ago - By: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

a month ago - By: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

a month ago - By: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

2 months ago - By: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

2 months ago - By: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

2 months ago - By: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

3 months ago - By: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

3 months ago - By: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

6 months ago - By: MediciNova, Inc.

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

6 months ago - By: MediciNova, Inc.

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

6 months ago - By: MediciNova, Inc.

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

6 months ago - By: MediciNova, Inc.

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

10 months ago - By: MediciNova, Inc.

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

10 months ago - By: MediciNova, Inc.

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

11 months ago - By: Benzinga - Mentions: ADSK ZTS VKTX PRCT

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

a year ago - By: MediciNova, Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

a year ago - By: MediciNova, Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

a year ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

a year ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

a year ago - By: MediciNova, Inc.

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

a year ago - By: MediciNova, Inc.

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

a year ago - By: Benzinga - Mentions: CYCC AZTR DBVT BIVI ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a year ago - By: MediciNova, Inc.

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

a year ago - By: MediciNova, Inc.

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

a year ago - By: MediciNova, Inc.

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

a year ago - By: MediciNova, Inc.

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

a year ago - By: MediciNova, Inc.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

a year ago - By: MediciNova, Inc.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

a year ago - By: MediciNova, Inc.

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

a year ago - By: MediciNova, Inc.

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

a year ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition